Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE)

Lung Cancer Clinical Trial

— ULYSSE  

Official title:

Prospective Longitudinal Cohort Associated to Blood Collection, Pathological Samples Collection, and Radiological and Pathological Imaging Collection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05267041
• Other study ID #: 69HCL21_1175
• Status: Recruiting
• Phase: N/A
• Start date: May 5, 2022
• Est. completion date: May 5, 2042

Study information

• Verified date: November 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 4000
• Est. completion date: May 5, 2042
• Est. primary completion date: May 5, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma…

• Diagnosis can be done:

• By cytology or pathologic assessment

• Or by multidisciplinary team meeting decision:

• Irradiation without morpho-metabolic sampling

• Treatment without sampling based on non-invasive molecular data

Exclusion Criteria:

• Refusal to participate

For optional blood sampling :

• < 30 kg for blood collection

• No blood sampling schedule for care

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• Quality of life questionnaire
One questionnaire between diagnostic annoucement and first line treatement

Biological:
• Blood sample
One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer

Other:
• Quality of life questionnaire
One questionnaire 6 months later after first line treatment
• Quality of life questionnaire
One questionnaire before second line treatment
• Quality of life questionnaire
One questionnaire 6 months later after second line treatment

Locations

Country	Name	City	State
France	Centre Hospitalier Lyon Sud	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants registered in the lung cancer database	cohort open to recruitment during 10 years with 10 years of patients follow-up	20 years